Allergan said it would support a shareholder proposal that will require “an independent board chair to be phased in during the next leadership transition.”
The announcement “reflects our board’s ongoing commitment to active board refreshment and governance best practices, as well as continuous engagement with our shareholders,” said Chris Coughlin, the lead independent director of Allergan’s board.
No further details about the proposal were disclosed.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
